Various studies have shown that potentially carcinogenic factor TAGLN2 is altered at the transcriptional and translational levels in a variety of malignancies, including as leukemia, breast cancer, colorectal cancer and lymphoma (Zhao et al., 2021; Pan et al., 2023). This evidence concerns the gene TAGLN2 and colorectal cancer.